Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration

Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy which may benefit from radioimmunotherapy. Previously, [177Lu]Lu-DOTA-C595 has been developed as a beta-emitting radioimmunoconjugate to target cancer-specific mucin 1 epitopes (MUC1-CE) overexpressed on PDAC. Ho...

Full description

Bibliographic Details
Main Authors: Ashleigh Hull, William Hsieh, Artem Borysenko, William Tieu, Dylan Bartholomeusz, Eva Bezak
Format: Article
Language:English
Published: SpringerOpen 2023-09-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
Actinium-225
Radioimmunotherapy
Pancreatic ductal adenocarcinoma
MUC1
Online Access:https://doi.org/10.1186/s41181-023-00209-z

Similar Items

Similar Items